| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Luwei Zhang CEO | XSHE Exchange | CNE1000065K2 ISIN |
| CN Country | 1,042 Employees | 30 Apr 2026 Last Dividend | 16 Apr 2025 Last Split | - IPO Date |
Newland Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) within China's pharmaceutical sector. Initially established as Henan Newland Pharmaceutical Co., Ltd., the company underwent a name change in June 2023 to better reflect its expanding scope and capabilities. Founded in 2005 and situated in Changge City, China, Newland Pharmaceutical Co., Ltd. represents a significant player in the pharmaceutical manufacturing industry, leveraging its extensive expertise to cater to the growing demands of both domestic and potential international markets.
Newland Pharmaceutical Co., Ltd. offers an extensive range of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), each playing a crucial role in the development and manufacturing of various medical treatments: